OBJECTIVE: The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) and indium-111 Octreotide single photon emission tomography ((111)In-Octreotide SPECT) in the evaluation of metastatic medullary thyroid carcinoma (MMTC). METHODS: Twenty-five MMTC patients were retrospectively evaluated. All patients had undergone whole-body (18)F-FDG-PET/CT including 20 who had also undergone (111)In-Octreotide SPECT within a maximum interval of 6 weeks. Diagnostic contrast-enhanced computed tomography (CT) alone or as part of (18)F-FDG-PET/CT examination was performed in all patients. RESULTS: Contrast-enhanced CT detected a total of 131 lesions including 79 enlarged lymph nodes and 14 bone lesions. (18)F-FDG-PET/CT visualized a total of 92 true positive lesions (SUVmax range 1.1-10.0, mean 4.0 ± 1.7) including 66 lymph nodes, 7 of which were not enlarged on CT, and 8 bone metastases. In the 20 patients studied with both techniques, a total of 64 and 46 true positive lesions were detected by (18)F-FDG-PET/CT and (111)In-Octreotide SPECT, respectively. In particular, (18)F-FDG uptake was found in 43 lymph nodes and in 7 bone metastases whereas (111)In-Octreotide uptake was detected in 27 lymph nodes and in 10 bone metastases. CONCLUSIONS: In MMTC patients, (18)F-FDG-PET/CT provides a useful contribution mainly in evaluating lymph node involvement whereas (111)In-Octreotide SPECT can contribute to the detection and somatostatin receptor characterization especially of bone lesions.

Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma / DE LUCA, Serena; Fonti, Rosa; Camera, Luigi; Salvatore, Barbara; Faggiano, Antongiulio; Ciarmiello, Andrea; Segreto, Sabrina; Colao, Annamaria; Salvatore, Marco; DEL VECCHIO, Silvana. - In: ANNALS OF NUCLEAR MEDICINE. - ISSN 0914-7187. - 30:3(2016), pp. 234-241. [10.1007/s12149-015-1056-5]

Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

DE LUCA, SERENA;Fonti, Rosa;CAMERA, LUIGI;FAGGIANO, ANTONGIULIO;SEGRETO, SABRINA;COLAO, ANNAMARIA;DEL VECCHIO, SILVANA
2016

Abstract

OBJECTIVE: The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) and indium-111 Octreotide single photon emission tomography ((111)In-Octreotide SPECT) in the evaluation of metastatic medullary thyroid carcinoma (MMTC). METHODS: Twenty-five MMTC patients were retrospectively evaluated. All patients had undergone whole-body (18)F-FDG-PET/CT including 20 who had also undergone (111)In-Octreotide SPECT within a maximum interval of 6 weeks. Diagnostic contrast-enhanced computed tomography (CT) alone or as part of (18)F-FDG-PET/CT examination was performed in all patients. RESULTS: Contrast-enhanced CT detected a total of 131 lesions including 79 enlarged lymph nodes and 14 bone lesions. (18)F-FDG-PET/CT visualized a total of 92 true positive lesions (SUVmax range 1.1-10.0, mean 4.0 ± 1.7) including 66 lymph nodes, 7 of which were not enlarged on CT, and 8 bone metastases. In the 20 patients studied with both techniques, a total of 64 and 46 true positive lesions were detected by (18)F-FDG-PET/CT and (111)In-Octreotide SPECT, respectively. In particular, (18)F-FDG uptake was found in 43 lymph nodes and in 7 bone metastases whereas (111)In-Octreotide uptake was detected in 27 lymph nodes and in 10 bone metastases. CONCLUSIONS: In MMTC patients, (18)F-FDG-PET/CT provides a useful contribution mainly in evaluating lymph node involvement whereas (111)In-Octreotide SPECT can contribute to the detection and somatostatin receptor characterization especially of bone lesions.
2016
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma / DE LUCA, Serena; Fonti, Rosa; Camera, Luigi; Salvatore, Barbara; Faggiano, Antongiulio; Ciarmiello, Andrea; Segreto, Sabrina; Colao, Annamaria; Salvatore, Marco; DEL VECCHIO, Silvana. - In: ANNALS OF NUCLEAR MEDICINE. - ISSN 0914-7187. - 30:3(2016), pp. 234-241. [10.1007/s12149-015-1056-5]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/622320
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact